Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria

Reuters

05-07

<a href="https://laohu8.com/S/IRON">Disc Medicine</a> Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria

Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria $(EPP.UK)$. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9445959-en) on May 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2533898420"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533898420\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2533898420?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533898420","market":"nz","top_or_hot":-1,"title":"Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria <a href=\"https://laohu8.com/S/EPP.UK\">$(EPP.UK)$</a>. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9445959-en) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-07 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria <a href=\"https://laohu8.com/S/EPP.UK\">$(EPP.UK)$</a>. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9445959-en) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nNDL3xFDlR:1","article_id":"2533898420","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533898420","pubTimestamp":1746619314,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria . This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application  in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera  in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IRON":"Disc Medicine","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Disc Medicine Inc.启动Bitopertin治疗红细胞生成性原卟啉症的APOLLO试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRON":0.9,"NDAQ":0.9},"content_text":"Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria\n    \n\n        Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria $(EPP.UK)$. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9445959-en) on May 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}